A-674563 hydrochloride

A-674563 hydrochloride is a potent and selective Akt1 inhibitor with K i of 11 nM. In Vitro A-674563 slows proliferation of tumor cells with an EC 50 of 0.4 μM. A563 (0-10 µM) significantly decreases GSK3 and MDM2 phosphorylation in STS cells. A563 shows inhibitory effect on all STS cell lines, with IC 50 values at 48 hours ranging from 0.22±0.034 µM (SW684) to 0.35 ±0.06 µM (SKLMS1). A563 induces G2 cell cycle arrest and apoptosis in STS cells. A563 (1 µM/12 hr) upregulates the expression of GADD45A independent of p53. A-674563 (10-1000 nM) is anti-proliferative and cytotoxic in cultured human melanoma cells, induces melanoma cell apoptotic death, inhibited by caspase inhibitors, and inhibits melanoma cells via Akt-dependent and -independent mechanisms. A-674563 is cytotoxic and anti-proliferative when added to U937 and AmL progenitor cells, activates caspase-3/9 and apoptosis in U937 and AmL progenitor cells, and manipulates other signalings in AmL cells whiling blocking Akt . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo A-674563 (40 mg/kg/d, p.o.) shows no significant monotherapy activity, but the efficacy of the combination therapy (A-674563+paclitaxel) is significantly improved in the PC-3 prostate cancer xenograft model. A-674563 (20, 100 mg/kg) increases plasma insulin in an oral glucose tolerance test . A563 (20 mg/kg/bid; p.o.) exhibits slow tumor growth and a significant difference in tumor volume without significant weight loss of mice. A563-treated tumors express increased levels of GADD45α and decreased levels of PCNA (a nuclear marker for proliferation). Additionally, TUNEL assay staining levels (marker for apoptosis) increase in the A563-treated specimens. A-674563 (25, 100 mg/kg, lavage daily) potently inhibits A375 xenograft growth in mice. A-674563 (15, 40 mg/kg) injection inhibits U937 xenograft in vivo growth, and improves mice survival. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Akt1 11 nM (Ki) PKA 16 nM (Ki) CDK2 46 nM (Ki) GSK3β 110 nM (Ki) ERK2 260 nM (Ki) PKCδ 360 nM (Ki) RSK2 580 nM (Ki) MAPK-AP2 1.1 μM (Ki) PKCγ 1.2 μM (Ki) Chk1 2.6 μM (Ki) CK2 5.4 μM (Ki) SRC 13 μM (Ki)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet